Search Results - "GALLWITZ, B"

The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems by Seufert, J., Gallwitz, B.

“…The glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) exenatide, liraglutide and lixisenatide have been shown to improve glycaemic control and beta‐cell…”
Get full text

Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data by Gallwitz, B

“…The therapeutic options for treating type 2 diabetes have been widened by the introduction of exenatide as the first incretin mimetic. Incretins are gut…”
Get more information

Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus by Kothny, W., Foley, J., Kozlovski, P., Shao, Q., Gallwitz, B., Lukashevich, V.

“…Aim The aim of this study is to assess the efficacy and safety of vildagliptin 50 mg bid as add‐on therapy to insulin in type 2 diabetes mellitus (T2DM)…”
Get full text

Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms by Schäfer, S. A, Tschritter, O, Machicao, F, Thamer, C, Stefan, N, Gallwitz, B, Holst, J. J, Dekker, J. M, t'Hart, L. M, Nijpels, G, van Haeften, T. W, Häring, H. U, Fritsche, A

“…Aims/hypothesis Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes and reduced insulin secretion. The…”
Get full text

Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans by Meier, J. J, Gethmann, A, Götze, O, Gallwitz, B, Holst, J. J, Schmidt, W. E, Nauck, M. A

“…Aims/hypothesis Diabetic dyslipidaemia contributes to the excess morbidity and mortality in patients with type 2 diabetes. Exogenous glucagon-like peptide 1…”
Get full text

Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial by Göke, B, Gallwitz, B, Eriksson, J, Hellqvist, A, Gause-Nilsson, I

“…To assess the efficacy and safety of saxagliptin vs. glipizide as add-on therapy to metformin in patients with type 2 diabetes mellitus and inadequate…”
Get more information

Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time by Gallwitz, B, Vaag, A, Falahati, A, Madsbad, S

“…To investigate the onset of treatment effects over time observed for liraglutide in combination with oral antidiabetic drugs (OADs). This analysis included…”
Get more information

A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion by Schäfer, S. A., Müssig, K., Staiger, H., Machicao, F., Stefan, N., Gallwitz, B., Häring, H. U., Fritsche, A.

“…Aims/hypothesis WFS1 type 2 diabetes risk variants appear to be associated with impaired beta cell function, although it is unclear whether insulin secretion…”
Get full text

Glucagon-like peptide-1 as a treatment option for type 2 diabetes and its role in restoring beta-cell mass by Gallwitz, B

“…The "incretin effect" describes the enhanced insulin response from orally ingested glucose compared with intravenous glucose leading to identical postprandial…”
Get more information

Hypothyroidism during second-line treatment of multidrug-resistant tuberculosis: a prospective study by Bares, R., Khalid, N., Daniel, H., Dittmann, H., Reimold, M., Gallwitz, B., Schmotzer, C.

“…SETTING: Hypothyroidism is an adverse effect of certain anti-tuberculosis drugs.DESIGN: This is a prospective study of the frequency and possible…”
Get full text

Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial by Ross, S. A., Caballero, A. E., Del Prato, S., Gallwitz, B., Lewis-D'Agostino, D., Bailes, Z., Thiemann, S., Patel, S., Woerle, H.-J., von Eynatten, M.

“…Aims To evaluate glucose‐lowering treatment strategies with linagliptin and metformin in people with newly diagnosed type 2 diabetes and marked hyperglycaemia,…”
Get full text

Type II diabetes and its therapy in clinical practice - results from the standardised non-interventional registry SIRTA by Gallwitz, B, Kusterer, K, Hildemann, S, Fresenius, K

“…Modern antidiabetic therapies should achieve low HbA1c values and avoid hypoglycaemic complications. The registry SIRTA included 1522 patients with type II…”
Get more information

Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association by Matthaei, S, Bierwirth, R, Fritsche, A, Gallwitz, B, Häring, H-U, Joost, H-G, Kellerer, M, Kloos, Ch, Kunt, T, Nauck, M, Schernthaner, G, Siegel, E, Thienel, F

Get more information

Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA₁c < 7% with no hypoglycaemia and no weight gain over 2 years by Gallwitz, B, Rosenstock, J, Emser, A, von Eynatten, M, Woerle, H-J

“…Linagliptin treatment for 104 weeks was recently reported to achieve non-inferior glucose-lowering effects compared with glimepiride in patients with type 2…”
Get more information

Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial by Gallwitz, B., Rosenstock, J., Patel, S., von Eynatten, M., Hehnke, U., Mehlburger, L., Dugi, K. A., Woerle, H.-J.

“…Aim To evaluate the risk of documented hypoglycaemia with glimepiride versus linagliptin. Methods This was an exploratory analysis of data from a 2‐year,…”
Get full text

Are there gender-specific differences concerning quality of life in treated acromegalic patients? by Psaras, T, Honegger, J, Gallwitz, B, Milian, M

“…Acromegaly is associated with deleterious comorbidities that can remain irreversible even after successful cure has been achieved and lead to a persistently…”
Get more information

Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study by Schernthaner, G., Rosas-Guzmán, J., Dotta, F., Guerci, B., Simó, R., Festa, A., Kiljański, J., Zhou, M., Gallwitz, B.

“…Aims To evaluate third‐line thiazolidinedione (TZD) or glimepiride therapy in patients inadequately controlled on metformin + exenatide twice daily, and…”
Get full text

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia by MEIER, J. J, GALLWITZ, B, SIEPMANN, N, HOLST, J. J, DEACON, C. F, SCHMIDT, W. E, NAUCK, M. A

Get full text

Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? by Meier, J J, Gallwitz, B, Schmidt, W E, Mügge, A, Nauck, M A

“…In the UGDP study, published in the 1970s, a high incidence of cardiovascular mortality was found in patients treated with the sulfonylurea agent tolbutamide…”
Get full text

Future perspectives for insulinotropic agents in the treatment of type 2 diabetes-DPP-4 inhibitors and sulphonylureas by Gallwitz, B, Häring, H.-U

“…The introduction of dipeptidyl-peptidase IV inhibitors (DPP-4 inhibitors) brought a novel class of insulinotropic agents into the treatment options for type 2…”
Get full text